Cargando…

Autoantibodies to Interferons in Infectious Diseases

Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Quiros-Roldan, Eugenia, Sottini, Alessandra, Signorini, Simona Giulia, Serana, Federico, Tiecco, Giorgio, Imberti, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223187/
https://www.ncbi.nlm.nih.gov/pubmed/37243300
http://dx.doi.org/10.3390/v15051215
_version_ 1785049881557073920
author Quiros-Roldan, Eugenia
Sottini, Alessandra
Signorini, Simona Giulia
Serana, Federico
Tiecco, Giorgio
Imberti, Luisa
author_facet Quiros-Roldan, Eugenia
Sottini, Alessandra
Signorini, Simona Giulia
Serana, Federico
Tiecco, Giorgio
Imberti, Luisa
author_sort Quiros-Roldan, Eugenia
collection PubMed
description Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infections with several agents. For instance, anti-type I interferon autoantibodies are implicated in Coronavirus Disease 19 (COVID-19) pathogenesis and found preferentially in patients with critical disease. However, autoantibodies were also described in the serum of patients with viral, bacterial, and fungal infections not associated with COVID-19. In this review, we provide an overview of anti-cytokine autoantibodies identified to date and their clinical associations; we also discuss whether they can act as enemies or friends, i.e., are capable of acting in a beneficial or harmful way, and if they may be linked to gender or immunosenescence. Understanding the mechanisms underlying the production of autoantibodies could improve the approach to treating some infections, focusing not only on pathogens, but also on the possibility of a low degree of autoimmunity in patients.
format Online
Article
Text
id pubmed-10223187
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102231872023-05-28 Autoantibodies to Interferons in Infectious Diseases Quiros-Roldan, Eugenia Sottini, Alessandra Signorini, Simona Giulia Serana, Federico Tiecco, Giorgio Imberti, Luisa Viruses Review Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infections with several agents. For instance, anti-type I interferon autoantibodies are implicated in Coronavirus Disease 19 (COVID-19) pathogenesis and found preferentially in patients with critical disease. However, autoantibodies were also described in the serum of patients with viral, bacterial, and fungal infections not associated with COVID-19. In this review, we provide an overview of anti-cytokine autoantibodies identified to date and their clinical associations; we also discuss whether they can act as enemies or friends, i.e., are capable of acting in a beneficial or harmful way, and if they may be linked to gender or immunosenescence. Understanding the mechanisms underlying the production of autoantibodies could improve the approach to treating some infections, focusing not only on pathogens, but also on the possibility of a low degree of autoimmunity in patients. MDPI 2023-05-22 /pmc/articles/PMC10223187/ /pubmed/37243300 http://dx.doi.org/10.3390/v15051215 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Quiros-Roldan, Eugenia
Sottini, Alessandra
Signorini, Simona Giulia
Serana, Federico
Tiecco, Giorgio
Imberti, Luisa
Autoantibodies to Interferons in Infectious Diseases
title Autoantibodies to Interferons in Infectious Diseases
title_full Autoantibodies to Interferons in Infectious Diseases
title_fullStr Autoantibodies to Interferons in Infectious Diseases
title_full_unstemmed Autoantibodies to Interferons in Infectious Diseases
title_short Autoantibodies to Interferons in Infectious Diseases
title_sort autoantibodies to interferons in infectious diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223187/
https://www.ncbi.nlm.nih.gov/pubmed/37243300
http://dx.doi.org/10.3390/v15051215
work_keys_str_mv AT quirosroldaneugenia autoantibodiestointerferonsininfectiousdiseases
AT sottinialessandra autoantibodiestointerferonsininfectiousdiseases
AT signorinisimonagiulia autoantibodiestointerferonsininfectiousdiseases
AT seranafederico autoantibodiestointerferonsininfectiousdiseases
AT tieccogiorgio autoantibodiestointerferonsininfectiousdiseases
AT imbertiluisa autoantibodiestointerferonsininfectiousdiseases